EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Pragmatische StudieOpen Access · CC BY 4.0

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis

Marta Simone, Roberto Palumbi, Mariaclara Achille, Stefania Micella, Mara Pascali, Antonia Peschechera, Alessandra Gabellone, Lucia Marzulli, Andrea De Giacomo, Giulia Maggi, Giorgio Reggiardo, Mariagrazia Felisi und 7 weitere

Neurological Sciences · 2025

DOI: 10.1007/s10072-025-08377-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neurological Sciences, 2025. Verfasst von Marta Simone und 18 weiteren Autor:innen. Beteiligte Einrichtung: Child Neuropsychiatry Unit, Department of Precision and Regenerative Medicine and Jonic Area (Dimepre-J), University of Bari "Aldo Moro, Bari, Italy.…. Hauptthemen laut MEDLINE: Glatiramer Acetate, Interferon beta-1a, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paediatric-onset Multiple Sclerosis (POMS) is a rare, highly active disease requiring timely disease-modifying therapy.

Objectives

This trial compared the efficacy and safety of intramuscular (i.m.) Interferon beta-1a (IFN-beta 1a) and subcutaneous (s.c.) Glatiramer Acetate (GA).

Methods

A 96-week, Phase IIIb, multicenter, open-label randomized trial enrolled 30 participants (ages 12–17). Patients were randomized into two groups: 15 received i.m. IFN-beta 1a, and 15 received s.c. GA. The primary endpoint was MRI disease activity-free status; secondary outcomes included annualized relapse rate (ARR), time to first relapse, Expanded Disability Status Scale (EDSS), cognitive and fatigue scores, and quality of life.

Results

The groups differed by age but not sex. MRI disease activity-free status did not differ ( p = 0.09). ARR was significantly lower in the GA group (0.20; 95% CI 0.08–0.42) than in the IFN-beta 1a group (0.57; 95% CI 0.31–0.95, p = 0.02). EDSS, cognitive, fatigue, and quality-of-life scores were comparable. Notably, 50% of GA patients and 30% of IFN-beta 1a patients switched to higher efficacy treatments.

Conclusions

Both treatments showed similar efficacy and safety, but early high-efficacy therapy may be preferable for POMS management. Trial Registration EudraCT Number: 2017–005129-18. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005129-18/IT

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glatiramer AcetateInterferon beta-1aMultiple SclerosisImmunologic FactorsHumansFemaleMaleChildAdolescentTreatment OutcomeInjections, SubcutaneousProspective StudiesInjections, IntramuscularQuality of Life

Stichwörter der Autor:innen

Glatiramer acetateInterferon beta-1aPOMSPhase III randomized clinical trialPragmatic study

Substanzen

Glatiramer AcetateInterferon beta-1aImmunologic Factors

Autor:innen und Institutionen

  • Child Neuropsychiatry Unit, Department of Precision and Regenerative Medicine and Jonic Area (Dimepre-J), University of Bari "Aldo Moro, Bari, Italy. simonemarta378@gmail.com.
  • Child Neuropsychiatry Unit, Department of Translational Biomedicines and Neurosciences (DiBrain), University of Bari "Aldo Moro, Bari, Italy.
  • Systems Medicine Department, University of Tor Vergata, Rome, Italy.
  • Child Neuropsychiatry Unit, Department of Precision and Regenerative Medicine and Jonic Area (Dimepre-J), University of Bari "Aldo Moro, Bari, Italy.
  • Consorzio Per Valutazioni Biologiche e Farmacologiche (CVBF), Bari, Italy.
  • TEDDY, European Network of Excellence for Paediatric Research, Pavia, Italy.

Förderung

  • Agenzia Italiana del Farmaco, Ministero della Salute

Zitieren

APA

Simone, M., Palumbi, R., Achille, M., Micella, S., Pascali, M., Peschechera, A., Gabellone, A., Marzulli, L., De Giacomo, A., Maggi, G., Reggiardo, G., Felisi, M., Padula, R., Bonifazi, D., Valeriani, M., Papetti, L., Lanzillo, R., Clerici, V. T., & Margari, L. (2025). A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis. Neurological Sciences. https://doi.org/10.1007/s10072-025-08377-3

Vancouver

Simone M, Palumbi R, Achille M, Micella S, Pascali M, Peschechera A, et al. A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis. Neurological Sciences. 2025. doi:10.1007/s10072-025-08377-3

BibTeX
@article{Simone2025,
  author = {Simone, Marta and Palumbi, Roberto and Achille, Mariaclara and Micella, Stefania and Pascali, Mara and Peschechera, Antonia and Gabellone, Alessandra and Marzulli, Lucia and De Giacomo, Andrea and Maggi, Giulia and Reggiardo, Giorgio and Felisi, Mariagrazia and Padula, Rosa and Bonifazi, Donato and Valeriani, Massimiliano and Papetti, Laura and Lanzillo, Roberta and Clerici, Valentina Torri and Margari, Lucia},
  title = {A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis},
  journal = {Neurological Sciences},
  year = {2025},
  doi = {10.1007/s10072-025-08377-3}
}
Kostenlos starten →